Form 8-K - Current report:
SEC Accession No. 0001437749-21-029035
Filing Date
2021-12-21
Accepted
2021-12-21 16:06:00
Documents
15
Period of Report
2021-12-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20211220_8k.htm   iXBRL 8-K 26579
2 EXHIBIT 99.1 ex_318037.htm EX-99.1 12116
7 logosmall.jpg GRAPHIC 5597
  Complete submission text file 0001437749-21-029035.txt   186556

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dffn-20211216.xsd EX-101.SCH 3594
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20211216_def.xml EX-101.DEF 11808
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20211216_lab.xml EX-101.LAB 15859
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20211216_pre.xml EX-101.PRE 12023
9 EXTRACTED XBRL INSTANCE DOCUMENT dffn20211220_8k_htm.xml XML 2663
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 211509186
SIC: 2834 Pharmaceutical Preparations